Skip to content
Enbrel(etanercept)
Enbrel, Erelzi (etanercept) is a protein pharmaceutical. Etanercept was first approved as Enbrel on . It is used to treat ankylosing spondylitis, juvenile arthritis, psoriatic arthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat ankylosing spondylitis, juvenile arthritis, psoriasis, psoriatic arthritis, and rheumatoid arthritis amongst others. The pharmaceutical is active against tumor necrosis factor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Enbrel, Erelzi (discontinued: Erelzi, Erelzi sensoready, Eticovo)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Etanercept
Tradename
Proper name
Company
Number
Date
Products
EnbreletanerceptImmunexN-103795 RX2020-03-05
1 products
Enbrel MinietanerceptImmunexN-103795 RX2017-09-14
1 products
EnbreletanerceptImmunexN-103795 RX
4 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
enbrelBiologic Licensing Application2021-12-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
ankylosing spondylitisEFO_0003898D013167M45
juvenile arthritisEFO_0002609D001171M08
psoriatic arthritisEFO_0003778D015535L40.5
rheumatoid arthritisEFO_0000685D001172M06.9
Agency Specific
FDA
EMA
Expiration
Code
etanercept, Enbrel, Immunex Corporation
2106-05-27Orphan excl.
etanercept, Enbrel Mini, Immunex Corporation
2106-05-27Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AB: Tumor necrosis factor alpha (tnf-alpha) inhibitors
— L04AB01: Etanercept
HCPCS
Code
Description
J1438
Injection, etanercept, 25 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
Clinical
Clinical Trials
382 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.976334734126
PsoriasisD011565EFO_0000676L403532272185
Ankylosing spondylitisD013167EFO_0003898M45—29171340
Psoriatic arthritisD015535EFO_0003778L40.5——671023
Juvenile arthritisD001171EFO_0002609M081272213
SpondylarthritisD025241—21417
SpondylarthropathiesD025242EFO_0000706M47—11315
Rheumatic feverD012213EFO_1001160I00-I02——11—2
HypertensionD006973EFO_0000537I10———112
GoutD006073EFO_0004274M10———1—1
Show 5 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 1 diabetes mellitusD003922EFO_0001359E10692——12
InflammationD007249—11—24
NeoplasmsD009369C80311——4
Metabolic syndromeD024821EFO_0000195E88.81—11—34
Prostatic neoplasmsD011471C61111——2
ArthritisD001168EFO_0005856M05-M14—11—12
PneumoniaD011014EFO_0003106J18111——2
DermatomyositisD003882EFO_0000398M33111——2
Granulomatosis with polyangiitisD014890EFO_0005297M31.3—21——2
Stevens-johnson syndromeD013262EFO_0004276L51.1——1——1
Show 13 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—102———12
Myelodysplastic syndromesD009190D4625———5
LeukemiaD007938C9514———4
Alzheimer diseaseD000544EFO_0000249F0331———4
Graft vs host diseaseD006086D89.81—4———4
Hidradenitis suppurativaD017497L73.2—2——13
Myelodysplastic-myeloproliferative diseasesD05443712———2
Discoid lupus erythematosusD008179L93.0—2———2
AsthmaD001249EFO_0000270J45—1——12
Respiratory distress syndromeD012128EFO_1000637J8012———2
Show 36 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.91———12
Hiv infectionsD015658EFO_0000764B201———12
Metabolic bone diseasesD001851HP_00009381————1
OsteoporosisD010024EFO_0003882M81.01————1
Persian gulf syndromeD018923EFO_00074301————1
Occupational diseasesD0097841————1
Castration-resistant prostatic neoplasmsD0641291————1
Therapeutic equivalencyD0138101————1
Subarachnoid hemorrhageD013345EFO_0000713I601————1
LymphomaD008223C85.91————1
Show 2 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Knee osteoarthritisD020370EFO_0004616M17————22
Papulosquamous skin diseasesD017444L40-L45————22
InfectionsD007239EFO_0000544————11
Behcet syndromeD001528EFO_0003780M35.2————11
Uveal diseasesD014603————11
Postoperative painD010149G89.18————11
Inguinal herniaD006552HP_0000023K40————11
BronchitisD001991J40————11
HyperlipidemiasD006949EFO_0003774E78.5————11
PregnancyD011247EFO_0002950Z33.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameETANERCEPT
INNetanercept
Description
Etanercept, sold under the brand name Enbrel among others, is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF, a soluble inflammatory cytokine) by acting as a TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. TNF-alpha is the "master regulator" of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF-alpha.
Classification
Protein
Drug classreceptor molecules or membrane ligands, natural, modified or modified: tumor necrosis factor receptors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID185243-69-0
RxCUI214555
ChEMBL IDCHEMBL1201572
ChEBI ID—
PubChem CID—
DrugBankDB00005
UNII IDOP401G7OJC (ChemIDplus, GSRS)
Target
Agency Approved
TNF
TNF
Organism
Homo sapiens
Gene name
TNF
Gene synonyms
TNFA, TNFSF2
NCBI Gene ID
Protein name
tumor necrosis factor
Protein synonyms
APC1 protein, Cachectin, TNF, macrophage-derived, TNF, monocyte-derived, TNF-a, TNF-alpha, tumor necrosis factor ligand 1F, Tumor necrosis factor ligand superfamily member 2, tumor necrosis factor-alpha, tumor necrotic factor alpha
Uniprot ID
Mouse ortholog
Tnf (21926)
tumor necrosis factor (P06804)
Alternate
No data
Variants
Clinical Variant
Identifier
Target mutation
Effect
Evaluation
Status
VCV000225964TNF, -488G>Adrug response2021-03-242B
Financial
Benepali - Biogen
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Enbrel - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Enbrel - Amgen
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 25,251 documents
View more details
Safety
Black-box Warning
Black-box warning for: Enbrel
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,884 adverse events reported
View more details